Abstract: The present invention relates to methods, kits and assay system for detecting drug-resistant Mycobacterium tuberculosis of suspected patient. The system of the present invention largely reduces the whole process of drug-resistant Mycobacterium tuberculosis detection to less than 5 hours.

Abstract: The present invention provides a method for preparing nucleic acid from a sample for detecting Mycobacterium comprises: (a) reducing the viscosity and decontaminating the sample by a reagent; (b) lysing the sample by adding an alkali solution; and (c) adjusting pH value by adding a pH-adjusting solution. Said method further comprises a method for concentrating the nucleic acid by using a nucleic acid-purifying column together with/without adding a protease into the treated sample. The present invention also provides a kit for preparing nucleic acid from a sample for detecting Mycobacterium comprises: (a) a solution of N-Acetyl-L-Cystein/Citrate/Sodium Hydroxide (NALC-Citrate-NaOH); (b) an alkali solution; and (c) a pH-adjusting solution. Said kit further comprises a nucleic acid-purifying column together with/without a protease.

Abstract: The present invention relates to a kit and method for detecting M. tuberculosis of suspected patient. The present invention also relates to primers and probe used to detect M. tuberculosis by performing one tube nested PCR.

Abstract: The present invention relates to an assay system and methods for detecting SARS coronavirus (SARS-CV) from the samples (especially for urine) of suspected patient in the control of SARS to provide updated information of prognosis as well as the criteria for discharging a recovered patient from a hospital. The present invention also relates to an apparatus for performing the integration of thermal and magnetic control in the same apparatus to largely reduce the time of hybridization less than 20 minutes and the whole process of SARS-CV detection is less than 5 hours.

Abstract: The present invention relates to methods, kits and assay system for detecting drug-resistant Mycobacterium tuberculosis of suspected patient. The system of the present invention largely reduces the whole process of drug-resistant M. tuberculosis detection in less than 5 hours.

Abstract: The present invention relates to a kit and method for detecting M. tuberculosis of suspected patient. The present invention also relates to primers and probe used to detect M. tuberculosis by performing one tube nested PCR.

Abstract: Scenario representation manipulation methods, scenario analysis devices, articles of manufacture, and data signals are described according to some aspects. In one aspect, a scenario representation manipulation method includes accessing a graphical representation comprising a plurality of nodes and a plurality of associations of the nodes, wherein the nodes and the associations of the nodes are indicative of a scenario, providing a plurality of defined structural arrangements, wherein the defined structural arrangements comprise a plurality of nodes and associations of the nodes, analyzing the nodes and associations of the nodes of the graphical representation using the defined structural arrangements, and generating another representation of the graphical representation responsive to the analyzing.

Abstract: Scenario analysis methods, scenario analysis devices, articles of manufacture, and data signals are described according to some aspects. In one aspect, a scenario analysis method includes accessing a representation of a first scenario, accessing a plurality of representations of a plurality of second scenarios, analyzing the representation of the first scenario with respect to the representations of the second scenarios, determining a plurality of relationships of the representation of the first scenario with respect to respective ones of the representations of the second scenarios responsive to the analyzing, and ranking the relationships.

Abstract: The present invention relates to DNA labeling reagents comprising a furocoumarin derivative and a detectable group with or without bound via a binding enhancer, and acridinium-9-carboxamide derivatives for use as chemiluminescent labels. The present invention also relates to a process of preparing DNA labeling compound.

Abstract: The present invention relates to DNA labeling reagents comprising a furocoumarin derivative and a detectable group with or without bound via a binding enhancer, and acridinium-9-carboxamide derivatives for use as chemiluminescent labels. The present invention also relates to a process of preparing DNA labeling compound.

Abstract: The present invention relates to DNA labeling reagents comprising a furocoumarin derivative and a detectable group with or without bound via a binding enhancer, and acridinium-9-carboxamide derivatives for use as chemiluminescent labels. The present invention also relates to a process of preparing DNA labeling compound.

Abstract: The present invention relates to DNA labeling reagents comprising a furocoumarin derivative and a detectable group with or without bound via a binding enhancer, and acridinium-9-carboxamide derivatives for use as chemiluminescent labels. The present invention also relates to a process of preparing DNA labeling compound.

Abstract: Potentially hazardous compositions containing solid combustible fuels, oxidants, nitro-containing, nitramine-containing or nitrato-containing compounds and, in many cases, binders are desensitized by electrolysis at low current and over an extended period of time. According to one disclosed method, compositions containing binders are first oxidized at the anode to cause decomposition and swelling of the binder, followed by further oxidation of the remaining components of the composition or switching of the polarity to cause reduction, as needed. According to another disclosed method, the composition is retained in a reaction vessel separate from the electrolysis cell, and the aqueous leachant from the composition is circulated in two portions through the two halves of the electrolysis cell to form strong oxidizing and reducing reagents, respectively, which are then circulated in succession through the reaction vessel to decompose the composition.